🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

FDA OKs Kyowa Kirin's mogamulizumab for two rare types of lymphoma

Published 08/08/2018, 11:49 AM
© Reuters.  FDA OKs Kyowa Kirin's mogamulizumab for two rare types of lymphoma
SGEN
-
TRIL
-
VRDN
-
  • The FDA approves Kyowa Kirin's Poteligeo (mogamulizumab-kpkc) for the treatment of adults with relapsed/refractory mycosis fungoides or Sézary syndrome after at least one prior line of systemic therapy. It is the first drug approved in the U.S. for the latter. Both are rare forms of cutaneous T-cell lymphoma.
  • Mogamulizumab is a monoclonal antibody that binds to (inhibits) a protein called CCR4 that plays a key role in regulating the trafficking of white blood cells called leukocytes.
  • Related tickers: (MGEN -4.9%)(TRIL +2.1%)(SGEN -0.7%)
  • Now read: FDA OKs first generic drug under new accelerated pathway


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.